GERON CORP Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments
GERON CORP (GERN) reported Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments of -$1.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-16.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2018-03-16
- GERON CORP available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2015 was -$1.00K.
- GERON CORP available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2011 was -$2.00K.
- GERON CORP available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2010 was $0.00.
- GERON CORP available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2009 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 12 month |
|---|---|
| 2015-12-31 | -$1.00K 10-K · filed 2018-03-16 |
| 2011-12-31 | -$2.00K 10-K · filed 2014-03-17 |
| 2010-12-31 | $0.00 10-K · filed 2012-03-07 |
| 2009-12-31 | $0.00 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |